insights_auto
Why is EDIT down 2,05%?
Dive Deeperchevron_right
EDIT:NASDAQ
Editas Medicine Inc
US$1,68
arrow_downward
-2,05%(-0,035) 1D
20 ພ.ຈ., 9 ໂມງ 32 ນາທີ 16 ວິນາທີ GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
US$1,69
High
US$1,71
Low
US$1,66
Mkt. cap
258,52 ລ້ານ
Avg. vol.
2,24 ລ້ານ
Volume
16,54 ພັນ
52-wk high
US$3,94
52-wk low
US$1,66
EPS
US$-0,62
Beta
2,09
Shares outstanding
154,34 ລ້ານ
No. of employees
87
Open
US$1,69
High
US$1,71
Low
US$1,66
Mkt. cap
258,52 ລ້ານ
Avg. vol.
2,24 ລ້ານ
Volume
16,54 ພັນ
52-wk high
US$3,94
52-wk low
US$1,66
EPS
US$-0,62
Beta
2,09
Shares outstanding
154,34 ລ້ານ
No. of employees
87
News stories
From web sources and news partners
Reuters
·
25 ນາທີກ່ອນ
SocGen sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
37 ນາທີກ່ອນ
Ryan Detrick: S&P 500 posts six-day losing streak, longest since April 2024
Bloomberg.com
·
55 ນາທີກ່ອນ
S&P 500 Faces Technical Make-or-Break Moment Below 7,200 Line
Barron's
·
2 ຊົ່ວໂມງກ່ອນ
S&P 500 Futures Decline in Premarket Trading; Lennar, Louisiana-Pacific Lag
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company that is developing therapies for rare diseases using CRISPR gene editing technology. Editas Medicine headquarters is located in Cambridge, Massachusetts with additional facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
CEO-
Employees87
Foundedພ.ຈ. 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteeditasmedicine.com